Bottom line
Is SBIO a good fund? The bottom line
SBIO is a managed health care sector ETF from Alps.
It charges 0.5% — about $50 a year on every $10,000 invested, cheaper than 81% of health care sector funds we track.
It returned +54.2% over one year, +0.7% a year over five years, +5.7% a year over ten (as of Dec 31, 2025, per its prospectus).
With $162 million in net assets and 89 holdings, its largest position is Alkermes Plc (4.5%) and the top 10 make up 34.8% of the portfolio.
What stands out
- Low cost: cheaper than 81% of health care sector peers
What to watch
- 5-year return in the bottom quarter of its category
Updated Nov 19, 2026
What SBIO invests in
The Fund seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (ticker symbol PMBI) (the Underlying Index).
The Fund employs a passive management or indexing investment approach designed to track the performance of the Underlying Index. The Underlying Index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration (FDA) clinical trials. In a Phase II trial, the drug is administered to a group of 100-300 people to see if it is effective and to evaluate its safety. In a Phase III trial, the drug is given to a larger group, between 500-3,000 people, to confirm its effectiveness, monitor side effects, compare it to commonly used treatments and collect information that will allow the drug or treatment to be used safely. Stocks selected for inclusion in the Underlying Index must be listed on a U.S. stock exchange. Underlying Index constituents must have a market capitalization of no less…
From the fund's prospectus (filed Mar 30, 2026).
SBIO performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| SBIO | +54.2% | +0.7% | +5.7% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What SBIO costs
On a $10,000 investment, SBIO's 0.5% expense ratio costs about $50 a year. The prospectus estimates $628 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
SBIO top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Alkermes Plc | 4.48% |
| 2 | Kymera Therapeutics Inc | 4.23% |
| 3 | Celcuity Inc | 3.92% |
| 4 | Mirum Pharmaceuticals Inc | 3.90% |
| 5 | Spyre Therapeutics Inc | 3.68% |
| 6 | Cg Oncology Inc | 3.35% |
| 7 | Apogee Therapeutics Inc | 2.93% |
| 8 | Xenon Pharmaceuticals Inc | 2.90% |
| 9 | Travere Therapeutics Inc | 2.77% |
| 10 | Dianthus Therapeutics Inc | 2.64% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 34.8% of the fund. See all top 25 holdings and asset mix →